Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CYNK-101 |
Synonyms | |
Therapy Description |
CYNK-101 consists of CD34+ human placental-derived allogeneic NK cells engineered to express a modified version of CD16, potentially resulting in antibody-dependent cellular cytotoxicity against tumor cells (Blood 2020; 136 (Supplement 1):1). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYNK-101 | CYNK 101|CYNK101 | CYNK-101 consists of CD34+ human placental-derived allogeneic NK cells engineered to express a modified version of CD16, potentially resulting in antibody-dependent cellular cytotoxicity against tumor cells (Blood 2020; 136 (Supplement 1):1). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|